BELLEVILLE, ON, Nov. 15, 2011 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, offers its sincere congratulations to Dr.
Alvaro Morales who became a Member of the Order of Canada earlier this
month in recognition of his contributions to advancing the field of
urology, notably in the areas of oncology and sexual dysfunction.
Dr. Morales was the Principal Investigator in the Phase I and II
clinical trials, as well as the first Phase III clinical trial with the
Company's Mycobacterial Cell Wall-DNA Complex (MCC) - trademarked Urocidin™ - in the treatment of bladder cancer. He has been an enthusiastic
supporter of this technology, believing that it could have fewer side
effects, better tolerability, and be safer for physicians to handle
than the current standard bladder cancer therapy, bacillus
During the 1970s while working in the Department of Urology at Queen's
University in Kingston, Ontario, Canada, Dr. Morales hypothesized that
infecting the bladder with BCG would provoke an immune system response
that would be sufficiently robust to eliminate some bladder tumours.
BCG is a live vaccine developed in the 1920s to prevent Tuberculosis in
humans. Dr. Morales' pioneering work formed the basis for registration
of BCG as a bladder cancer therapy. Since that registration, he has
been anticipating a new generation of therapy.
"We are proud to have had Dr. Morales as a colleague and friend of our
Company for more than 25 years," said Mr. Graeme McRae, Chairman,
President & CEO of Bioniche Life Sciences Inc. "The Member of the Order
of Canada recognizes his lifetime of distinguished service to the field
of urology and his unwavering commitment to finding efficacious
therapies for bladder cancer patients."
About the Order of Canada
Established in 1967 by Her Majesty Queen Elizabeth II, the Order of
Canada is the centrepiece of Canada's honours system and recognizes a
lifetime of outstanding achievement, dedication to the community and
service to the nation. The Order recognizes people in all sectors of
Canadian society. Their contributions are varied, yet they have all
enriched the lives of others and made a difference to this country. The
Order of Canada's motto is DESIDERANTES MELIOREM PATRIAM (They desire a
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2010. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097